leisure time -WSS

leisure time

author：entertainment 2025-09-28 17:43:43 - browse：4561

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： Roche drug slashes death risk in early

focus

WSS

Pushing for an NIH office for post

FDA advisers back CAR

STAT Readout: Friday, Oct. 20 biotech updates

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Is there really a nursing shortage in the U.S.?

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

focus

leisure time

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Jerome Adams on the need for new antivirals for Covid

STAT Summit: Ending the crisis of Black deaths in the U.S.

BioMarin wins approval for gene therapy to treat hemophilia A

Male and female sex labels in research insufficient, scientists say

Malaria cases in Florida and Texas: Here’s what you need to know

Amid AI frenzy, a top HHS official's quest to create safeguards

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

entertainment

Pushing for an NIH office for post

WuXi out of biotech trade group, U.S. and China relations to blame

Is there really a nursing shortage in the U.S.?

Why depression after traumatic brain injury is distinct

As AI in medicine takes off, can 'human in the loop' prevent harm?

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Wikipedia

focus

hotspot

knowledge